Samsung Bioepis "Renflexis Switch Prescription 1-Year Retention Rate 83%"

[Asia Economy Reporter Cho Hyun-ui] Samsung Bioepis announced on the 27th that the rate of patients maintaining prescriptions for more than one year after switching from the original drug or biosimilar containing infliximab to 'Renflexis' is 83%.

Samsung Bioepis revealed two pieces of 'real-world data' based on these results at the American College of Gastroenterology (ACG) Annual Scientific Meeting. This is the first time real-world data of Renflexis based on prescription cases in the United States has been disclosed.

Samsung Bioepis's Renflexis is a biosimilar of Janssen's autoimmune treatment 'Remicade' and is used for autoimmune diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis.

A study based on data from 3,204 patients with inflammatory bowel disease compared the time it took for Renflexis to become the most frequently used product among patients newly prescribed infliximab-containing drugs. As a result, Renflexis was faster at 2 months compared to other biosimilar products at 5 months.

Kim Hee-kyung, Executive Director of Clinical Medicine at Samsung Bioepis, said, "Through the real-world data confirmed this time, we were able to see that our product offers a positive treatment alternative to patients," adding, "We will continue to strive to establish Renflexis as a more trusted product in the U.S. market."

This content was produced with the assistance of AI translation services.